Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2
Mortensen ACL, Morin E, Brown CJ, Lane DP, Nestor M.
EJNMMI Research. 2020. 10:38.
This study investigated the combination of targeted nuclear therapy with radiosensitizing agents. More specifically, LigandTracer Yellow was used to follow the uptake of the 177Lu-labeled anti-CD44v6 antibody AbN44v6 to HCT116 and UM-SCC-74B cells. The signal height from the two cell lines correlated with their antigen expression, indicating specificity.